BIOflex Technologies Announces Listing on the Frankfurt Stock Exchange

MONTREAL, QUEBEC--(Marketwired - Sept. 22, 2015) - BIOflex Technologies Inc. (TSX VENTURE:BFT)(FRANKFURT:6BX) (the "Company" or "BIOflex") announces the listing of its common shares for trading on the Frankfurt Stock Exchange under the symbol "6BX". The Company's common shares now trade concurrently on the Frankfurt Stock Exchange and on the TSX Venture Exchange under the symbol "BFT".

The Frankfurt Stock Exchange is one of the world's largest (behind only the Nasdaq and NYSE) organized exchange-trading market in terms of turnover and dealings in securities. The electronic trading platform of the Frankfurt Stock Exchange, XETRA, has made it the world's second-largest fully electronic cash market. This European listing will help to increase the Company's trading liquidity and facilitate investment in BIOflex by European investors. BIOflex stock quotes may be checked online at www.boerse-frankfurt.de/en/equities/bioflex+technologies+inc+CA09074C2040.

BIOflex CEO Ms. Leena Lakdawala states, "Listing BIOflex on the Frankfurt Stock Exchange as well as the TSX Venture Exchange will give the Company exposure to a much larger potential investor base. BIOflex has not only listed its shares in Europe but will also be targeting the multibillion dollar European health and wellness device market for the first time. We feel this is a great opportunity for BIOflex to introduce the company and its unique products to a receptive European investing audience."

In other news, BIOflex is pleased to announce the appointment of Ms. Kristine Dorward to the board of directors. Ms. Dorward is Director of Marketing and Business Development at Prometic Life Sciences, joining the organization in 2014. Having worked in the pharmaceutical and biotechnology industry for more than 17 years, Kristine has held senior positions in licensing, acquisitions, marketing and sales with geographical scope encompassing both North American and global markets. Acting in strategic leadership roles, Kristine has contributed to the successful launch of products in multiple therapeutic areas and has completed numerous due diligence evaluations as part of pipeline planning and expansion efforts to drive corporate growth. Kristine holds an MBA, BSc, CLP designation with CVA credential in progress.

BIOflex CEO Ms. Leena Lakdawala states, "We are pleased to welcome Kristine to the board of BIOflex and believe her extensive corporate experience will complement our strong team of executives."

About BIOflex Technologies Inc.

BIOflex Technologies manufactures and distributes patented magnetic devices designed for the consumer market seeking relief from pain. The patented product line consists of more than 20 products for the knees, elbows, ankles, back and shins. The company is currently developing other products including a line of sleep and wellness products, all designed to treat pain and enhance physical well-being.

The Company intends to sell its products through several channels including direct, web-based sales; corporate partnerships; television shopping channels; retail distribution; internet catalogs; and through a network of distributors worldwide. Several of the Company's products are registered with the FDA as Class I medical devices.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the business and operations of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of the Company to execute and achieve its business objectives. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.